Palvella Therapeutics, Inc. Interest Income (Expense), Net
Palvella Therapeutics, Inc. (PVLA) reported Interest Income (Expense), Net of $1.97 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNet · last filed 2026-08-04
- Palvella Therapeutics, Inc. interest income (expense), net for the quarter ending 2026-06-30 was $1.97M, a 184.78% increase year-over-year.
- Palvella Therapeutics, Inc. interest income (expense), net for the quarter ending 2026-03-31 was $1.07M, a 42.69% increase year-over-year.
- Palvella Therapeutics, Inc. interest income (expense), net for the quarter ending 2025-12-31 was $520.00K, a 85.05% increase year-over-year.
- Palvella Therapeutics, Inc. interest income (expense), net for the quarter ending 2025-09-30 was $628.00K, a 235.83% increase year-over-year.
- Palvella Therapeutics, Inc. interest income (expense), net for fiscal 2025 was $2.59M, a 303.43% increase from fiscal 2024.
- Palvella Therapeutics, Inc. interest income (expense), net for fiscal 2024 was $642.00K.
| Period end | Interest Income (Expense), Net 3 month | Interest Income (Expense), Net 6 month | Interest Income (Expense), Net 9 month | Interest Income (Expense), Net 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.97M 10-Q · filed 2026-08-04 | $3.04M 10-Q · filed 2026-08-04 | $3.56M derived: sum of 3 quarters · filed 2026-08-04 | $4.19M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $1.07M 10-Q · filed 2026-05-07 | $1.59M derived: sum of 2 quarters · filed 2026-05-07 | $2.22M derived: sum of 3 quarters · filed 2026-05-07 | $2.91M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $520.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $1.15M derived: sum of 2 quarters · filed 2026-03-31 | $1.84M derived: sum of 3 quarters · filed 2026-08-04 | $2.59M 10-K · filed 2026-03-31 |
| 2025-09-30 | $628.00K 10-Q · filed 2025-11-12 | $1.32M derived: sum of 2 quarters · filed 2026-08-04 | $2.07M 10-Q · filed 2025-11-12 | $2.35M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $690.00K 10-Q · filed 2026-08-04 | $1.44M 10-Q · filed 2026-08-04 | $1.72M derived: sum of 3 quarters · filed 2026-08-04 | $1.91M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $752.00K 10-Q · filed 2026-05-07 | $1.03M derived: sum of 2 quarters · filed 2026-05-07 | $1.22M derived: sum of 3 quarters · filed 2026-05-07 | $1.13M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $281.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $468.00K derived: sum of 2 quarters · filed 2026-03-31 | $382.00K derived: sum of 3 quarters · filed 2026-03-31 | $642.00K 10-K · filed 2026-03-31 |
| 2024-09-30 | $187.00K 10-Q · filed 2025-11-12 | $101.00K derived: sum of 2 quarters · filed 2025-11-12 | $361.00K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$86.00K 10-Q · filed 2025-08-14 | $0.00 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $86.00K 10-Q · filed 2025-05-15 | |||
| 2015-09-30 | -$4.22K 10-Q · filed 2015-11-13 | |||
| 2014-09-30 | -$181.21K 10-Q · filed 2015-11-13 | -$404.29K 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |